235 (PB115) - Phase II trial of afatinib in patients with EGFR-mutated solid tumors excluding lung cancer: results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A

Abstract

Background: Molecularly targeted treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have prolonged survival of pts with activating EGFR mutations in non-small cell lung cancer (NSCLC). Afatinib is an ErbB family blocker that demonstrated clinical benefit in pts with NSCLC with common and uncommon activating EGFR mutations. The activity of afatinib in other tumor types with EGFR mutations is less well known. National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) Arm EAY131-A evaluated afatinib in tumors beyond lung cancer that harbored EGFR activating alterations.